SUCCESSOR-1

Phase 3 Clinical Trial Evaluating the Safety and Effectiveness of Investigational Drug Mezigdomide in Combination with Bortezomib and Dexamethasone Compared to Pomalidomide, Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma

What's the purpose of the trial?

The goal of this clinical trial is to learn more about the safety and effectiveness of investigational drug Mezigdomide given in combination with approved treatments Bortezomib and Dexamethasone. Researchers will compare this investigational combination against standard of care treatments Pomalidomide, Bortezomib and Dexamethasone to learn more about how Mezigdomide works in relapsed or refractory multiple myeloma. 

Trial status

Accepting patients

Phase
Phase 3
Enrollment
810
Last Updated
2 weeks ago
Am I Eligible

Participating Centers

There are 33 centers participating in this trial. Enter a location below to find the closest center.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

  • Bortezomib
  • Dexamethasone
  • Mezigdomide
  • Pomalidomide

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Accepting patients

Mezigdomide + Bortezomib + Dexamethasone

Accepting patients

Pomalidomide + Bortezomib + Dexamethasone

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print this trial to share with your doctor.

(888) 354-2873

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.